American Clinical Research Holdings, a clinical trial site management organization formed by Latticework Capital Management, has acquired Catalina Research Institute, an independent clinical trials center.

CRI is focused on improving the quality of life for Americans through scientific research, with a specific presence in serving underrepresented populations. With this acquisition, ACRS aims to increase efficiencies within its sector given the complexity of clinical trials and challenges with patient recruitment. The partnership will also allow for CRI’s expansion as a full-service provider of trial needs from phase one through drug commercialization. LCM managing partner Kyle Bradford, managing partner Steve Neumann, vice president Brett Lacher, and associate Nina Saboorian worked on the transaction.

“CRI has mastered the management of complex clinical trials and we’re confident in our ability to build a scalable network of owned and operated sites collectively benefitting from sharing best practices, standard operating procedures, budgeting and contracting processes,” says Bradford. “With record amounts of capital being raised by pharma and biotech companies, CRI’s growth, supported by ACRS, will be a model for the future of SMOs working to expand their clinical trial pipelines and increase revenue.”

McGuireWoods LLP represented Latticework in the transaction.